Monitoring the safety of licensed medicines


The withdrawal of the selective cyclooxygenase 2 inhibitor rofecoxib owing to cardiovascular side effects ignited debate about the need for major changes to current mechanisms for post-marketing surveillance (PMS) of drug safety. Here, we discuss the current mechanisms, whether they are being used appropriately, and consider the need for changes to regulatory systems.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Fitzgerald, G. A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351, 1709–1711 (2004).

    CAS  Article  Google Scholar 

  2. 2

    Topol, E. J. Failing public health — rofecoxib, Merck and the FDA. N. Engl. J. Med. 351, 1707–1709 (2004).

    CAS  Article  Google Scholar 

  3. 3

    Frantz, S. How to avoid another 'Vioxx'. Nature Rev. Drug Discov. 4, 5–7 (2005).

    CAS  Article  Google Scholar 

  4. 4

    Belton, K. J. and the European Pharmacovigilance Research Group Attitude survey of adverse drug reaction reporting by health care professionals across the European Union. Eur. J. Clin. Pharmacol. 6, 423–427 (1997).

    Article  Google Scholar 

  5. 5

    Mann, R. D. Prescription Event Monitoring — recent progress and future horizons. Br. J. Clin. Pharmacol. 46, 195–201 (1998).

    CAS  Article  Google Scholar 

  6. 6

    Safety Assessment of Marketed Medicines. Guidelines for company sponsored safety assessment of marketed medicines. (London MCA, 1993).

  7. 7

    Griffin, M. R., Stein, M. S. & Ray, W. A. Post marketing surveillance for drug safety; surely we can do better. Clin. Pharmacol. Ther. 75, 491–494 (2004)

    Article  Google Scholar 

  8. 8

    Report of the Committee on Safety of Medicines Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants (The Stationery Office, London, 45, 2004).

  9. 9

    Jick, H., Kaye, J. & Jick, S. Antidepressants and the risk of suicidal behaviours. JAMA 292, 338–343 (2004)

    CAS  Article  Google Scholar 

  10. 10

    Glaxo SmithKline. Report quoted in the Committee on Safety of Medicines Expert Working Group on the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants (The Stationery Office, London, 103–104, 2004).

  11. 11

    Martinez, C. et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case control study. Br. Med. J. 330, 389 (2005).

    CAS  Article  Google Scholar 

  12. 12

    Bresalier, R. S. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092–1102 (2005).

    CAS  Article  Google Scholar 

  13. 13

    Rubenstein, S. How best to monitor drugs after they're FDA approved. Q&A Wall Street Journal (20 Dec 2004).

Download references

Author information



Corresponding author

Correspondence to Alasdair Breckenridge.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

Related links


Medicines and Healthcare products Regulatory Agency

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Breckenridge, A., Woods, K. & Raine, J. Monitoring the safety of licensed medicines. Nat Rev Drug Discov 4, 541–543 (2005).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing